PolarityBio's Participation at SAWC Fall 2025
PolarityBio, a prominent clinical-stage biotechnology company dedicated to improving wound healing, announces its upcoming involvement in the Symposium on Advanced Wound Care (SAWC) Fall 2025. The event is set to take place from September 3-6 in Las Vegas.
Transformational Collaboration in Patient Care
John Stetson, CEO of PolarityBio, expressed enthusiasm about participating in the SAWC community, emphasizing the importance of sharing insights and ideas to enhance patient care through regenerative technologies. The company is committed to engaging with a variety of professionals, including clinicians and researchers, to collectively address pressing patient care challenges.
The Importance of SAWC Fall
SAWC Fall ranks as the largest multidisciplinary meeting focused on wound care in the United States. It facilitates collaboration among clinicians, researchers, and industry leaders over four days of enriching evidence-based education. This year's conference features over 50 scientific sessions led by 55 world-renowned faculty members, with specialized tracks dedicated to critical topics such as pressure injury prevention and the economics surrounding wound care.
The Challenge of Chronic Wounds
Chronic wounds impact approximately 6.7 million Americans, leading to increased hospitalization and the need for amputations. Recognizing this urgent health issue, SAWC's focus on interdisciplinary approaches complements PolarityBio's mission to elevate patient outcomes through cutting-edge, science-driven solutions.
Innovative Solutions from PolarityBio
As a frontrunner in autologous skin regeneration, PolarityBio distinguishes itself by utilizing the stem cell populations found within the patient's skin to address chronic wounds innovatively. Their leading product, SkinTE®, serves as a first-of-its-kind biologic therapy that is actively pursuing FDA Biologics License Application (BLA) approval specifically for diabetic foot ulcers (DFUs). With Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) Designations from the FDA, SkinTE® has demonstrated promising improvements compared to traditional therapies in Phase II trials.
Future Directions for PolarityBio
The Phase III Pivotal Study, known as COVER DFUS II, is in the final stages of enrollment, set to conclude in November 2025. Completion of this study will provide crucial data for the BLA submission expected in the first half of 2026. Given the absence of BLA-approved therapies for chronic wounds since 1997, PolarityBio is poised to impact treatment methodologies significantly and strives to network with other industry leaders at SAWC to forge a new path in wound healing.
Connecting with Wound Care Leaders
PolarityBio extends an invitation to all wound healing professionals attending SAWC Fall 2025 to engage and discuss potential collaborations. Interested parties can arrange meetings in advance by reaching out to PolarityBio directly.
About PolarityBio
Headquartered in Salt Lake City, Utah, PolarityBio is committed to developing innovative regenerative biologics. The company's pioneering product, SkinTE®, focuses on autologous skin therapy designed to promote wound healing. Currently, PolarityBio holds an investigational new drug application (IND) for SkinTE® with the FDA and is conducting the final pivotal study needed for BLA submission for diabetic foot ulcers. Visit www.polaritybio.com for more information.
Frequently Asked Questions
What is PolarityBio's main focus?
PolarityBio primarily focuses on developing innovative solutions for wound healing through autologous regenerative therapies.
When will PolarityBio participate in the SAWC Fall 2025?
PolarityBio will participate in the SAWC Fall from September 3-6, 2025, in Las Vegas.
What is SkinTE®?
SkinTE® is an autologous skin multicellular therapy developed by PolarityBio that utilizes the patient's own cells to treat chronic wounds, particularly diabetic foot ulcers.
What certifications has SkinTE® received?
SkinTE® has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
How can I connect with PolarityBio during SAWC?
You can arrange meetings with PolarityBio representatives by contacting them directly prior to the event.
